Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 20/20 | 1.00 |
| ▸ | ATR | Q13535 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.78 |
| ▸ | MTOR | P42345 | 11/20 | 0.73 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18631949 | 0.99 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL29565807 | 0.99 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18631935 | 0.97 | ATM (0.97) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL19584960 | 0.91 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18824736 | 0.89 | ATM (0.81) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18631986 | 0.88 | ATM (0.79) | ATMATRKCNH2MTORPIK3CA | |
| Azd-1390 SCHEMBL18631972 | 0.88 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL19585078 | 0.88 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| Azd-1390 SCHEMBL29565675 | 0.88 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL19585082 | 0.88 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-03-28 | — | — | US | claimed |
| EP-3683220-B1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF HUNTINGTON'S DISEASE | ASTRAZENECA AB (SE) | 2022-04-13 | — | — | EP | claimed |
| US-20210147416-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2021-05-20 | — | — | US | claimed |
| EP-3350180-B1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2020-11-11 | — | — | EP | claimed |
| CN-108137576-B | 8- [6- [3- (amino) propoxy ] -3-pyridyl ] -1-isopropyl-imidazo [4,5-C ] quinolin-2-one derivatives | 阿斯利康(瑞典)有限公司 | 2020-09-22 | — | — | CN | claimed |
| EP-3683220-A1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF HUNTIGTON'S DISEASE | Astrazeneca AB (SE) | 2020-07-22 | — | — | EP | claimed |
| US-10457679-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-10-29 | — | — | US | claimed |
| US-20180141943-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2018-05-24 | — | — | US | claimed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | claimed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-08-17 | — | — | US | disclosed |
| CN-116194109-A | Combination of antibody-drug conjugate and ATM inhibitor | 阿斯利康(英国)有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-9856255-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-01-02 | — | — | US | disclosed |
| US-9856255-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-01-02 | — | — | US | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| WO-2017046216-A1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1 -ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147416-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885ATR 9/4885KCNH2 2539/4885 |
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ATM, CHEK2, ERBB2 | ATM 1/4885ATR 7/4885KCNH2 4793/4885 |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, BRCA1, CHEK2 | ATM 1/4885ATR 10/4885KCNH2 2560/4885 |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885ATR 10/4885KCNH2 2560/4885 |
| US-10457679-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, BRCA1, CHEK2 | ATM 1/4885ATR 10/4885KCNH2 2645/4885 |
| US-20180141943-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885ATR 10/4885KCNH2 2645/4885 |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885ATR 10/4885KCNH2 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.